Key statistics
On Wednesday, Evotec SE (1EVT:MIL) closed at 8.35, 61.26% above the 52 week low of 5.18 set on Oct 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.58 |
---|---|
High | 8.58 |
Low | 8.35 |
Bid | -- |
Offer | -- |
Previous close | 8.80 |
Average volume | 121.90 |
---|---|
Shares outstanding | 177.76m |
Free float | 158.04m |
P/E (TTM) | -- |
Market cap | 1.54bn EUR |
EPS (TTM) | -0.9668 EUR |
Data delayed at least 15 minutes, as of Feb 12 2025 13:35 GMT.
More ▼
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-DD: Evotec SE: Dr. Cord Dohrmann, Exercise against Cash Settlement (Share Performance Plan)
- EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk
- EQS-PVR: Evotec SE: Correction of a release from 27/11/2024 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
More ▼